RNA Therapeutics in Cardiovascular Medicine: From Molecular Mechanisms to Clinical Practice

RNA therapeutics are an exciting class of medications that target RNA and/or are themselves made from RNA. Most RNA therapeutics that have been approved for clinical use are antisense oligonucleotides or small interfering RNAs. To date, eight RNA therapeutics with cardiovascular relevance have received US Food and Drug Administration approval, but not all of them have specific indications for treating cardiovascular disease. There is a promising pipeline of additional cardiovascular RNA therapies targeting lipoprotein(a), angiopoietin-like protein 3, and angiotensinogen. Chemical modifications to therapeutic nucleic acids are important for conferring nuclease resistance and limiting immunostimulation in vivo, and enhanced delivery can be achieved using N -acetylgalactosamine conjugation and/or lipid nanoparticles. Emerging approaches include stereopure oligonucleotide chemistry, circular RNAs, adenosine-to-inosine RNA base editing, and nonhepatic targeting. This review summarizes the mechanistic basis of each modality, the clinical evidence for approved cardiovascular RNA therapeutics, selected pipeline candidates in advanced trials, and directions for future development.

Authors

Institutions

Publication Details

Journal
Annual Review of Medicine
Published
2026-11-16
DOI
https://doi.org/10.1146/annurev-med-042425-070657
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

RNA Therapeutics in Cardiovascular Medicine: From Molecular Mechanisms to Clinical Practice

Christopher L. Holley
Annual Review of Medicine
RNA Interference and Gene Delivery
article

RNA Therapeutics in Cardiovascular Medicine: From Molecular Mechanisms to Clinical Practice

Christopher L. Holley
article en

Abstract

RNA therapeutics are an exciting class of medications that target RNA and/or are themselves made from RNA. Most RNA therapeutics that have been approved for clinical use are antisense oligonucleotides or small interfering RNAs. To date, eight RNA therapeutics with cardiovascular relevance have received US Food and Drug Administration approval, but not all of them have specific indications for treating cardiovascular disease. There is a promising pipeline of additional cardiovascular RNA therapies targeting lipoprotein(a), angiopoietin-like protein 3, and angiotensinogen. Chemical modifications to therapeutic nucleic acids are important for conferring nuclease resistance and limiting immunostimulation in vivo, and enhanced delivery can be achieved using N -acetylgalactosamine conjugation and/or lipid nanoparticles. Emerging approaches include stereopure oligonucleotide chemistry, circular RNAs, adenosine-to-inosine RNA base editing, and nonhepatic targeting. This review summarizes the mechanistic basis of each modality, the clinical evidence for approved cardiovascular RNA therapeutics, selected pipeline candidates in advanced trials, and directions for future development.

Annual Review of Medicine
Duke University (US)
Good health and well-being
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon